A new system for regional citrate anticoagulation in continuous venovenous hemodialysis (CVVHD)

Clinical Nephrology

Volumn 59, Issue 2, 2003, Pages 106-114

  Mitchell, A ^a   Daul, A E ^a   Beiderlinden, M ^a   Schafers R F ^a   Heemann, U ^a   Kribben, A ^a   Peters, J ^a   Philipp, T ^a   Wenzel, R R ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Bicarbonate buffered dialysate; Continuous venovenous hemodialysis; CVVHD; Regional citrate anticoagulation

Indexed keywords

ACID; ACID CITRATE DEXTROSE; ANTICOAGULANT AGENT; BASE; BICARBONATE; CALCIUM; CITRATE TRISODIUM; CITRIC ACID; CREATININE; ELECTROLYTE; GLUCONATE CALCIUM; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NAFAMSTAT; PROSTACYCLIN; PROTAMINE SULFATE; SERINE PROTEINASE INHIBITOR; SODIUM;

ACID BASE BALANCE; ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD FLOW VELOCITY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; CRITICAL ILLNESS; DIALYSATE LEVEL; DIALYSIS MEMBRANE; DRUG MECHANISM; ELECTROLYTE BALANCE; FEMALE; HEMODIALYSIS; HUMAN; HYPERNATREMIA; HYPOCALCEMIA; INFUSION; MALE; MEMBRANE FILTER; METABOLIC ALKALOSIS; SAFETY; SODIUM BLOOD LEVEL; TETANIC SPASM; VALIDATION PROCESS;

EID: 0037322192     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP59106     Document Type: Article

References (30)

1. Baldwin J, Bellomo R 1999 Flow reductions associated with CVVH: A comparison of frequency, severity and duration between access catheter sites. Blood Purif 17: 9A
2. Bartlett H 1996 Continuous renal replacement therapy in multiple organ failure. Am J Kidney Dis 34: 97-99
3. Bartlett H, Bosch J, Geronemus R, Paganini E, Ronco C, Swartz R 1988 Continuous arteriovenous hemofiltration for acute renal failure. ASAIO Trans 34: 67-77
4. Bunker J, Bendixen H, AJM 1962 Hemodynamic effects of intravenously administered sodium citrate. N Engl J Med 266: 372-377
5. Bunker J, Stetson J, Coe R, Grillo H, Murphy A 1955 Citric acid intoxication. JAMA 157: 1361-1367
6. Davenport A, Will EJ, Davidson AM 1993 Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 21: 328-338
7. Hory B, Cachoux A, Toulemonde F 1985 Continuous arteriovenous hemofiltration with low-molecular weight heparin (letter). Nephron 42: 125
8. Kaplan AA, Petrillo R 1987 Regional heparinization for continuous arterio-venous hemofiltration (CAVH). ASAIO Trans 33: 312-315
9. Kierdorf HP 1995 The nutritional management of acute renal failure in the intensive care unit. New Horiz 3: 699-707
10. Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT 2000 Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis 35: 802-811
11. Lauer A, Alvis R, Avram M 1988 Hemodynamic consequences of continuous arteriovenous hemofiltration. Am J Kidney Dis 12: 110-115
12. Lehninger AL, 1982 Principles of Biochemistry. Worth Publishers Inc., New York
13. Lowenstein JM 1967 The tricarboxylic acid cycle. In: Greenberg DM (ed) Metabolic Pathways 1967. Academic Press, New York, pp 146-270
14. Maher JF, Lapierre L, Schreiner GE, Geiger M, Westervelt FBJ 1963 Regional heparinization for hemodialysis: technique and clinical experiences. N Engl J Med 268: 451-456
15. Mehta RL 1996 Anticoagulation strategies for continuous renal replacement therapies: What works? Am J Kidney Dis 28: S8-S14
16. Mehta RL, McDonald BR, Aguilar MM, Ward DM 1990 Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. Kidney Int 38: 976-981
17. Meier-Kriesche HU, Finkel KW, Gitomer JJ, DuBose TD 1999 Unexpected severe hypocalcemia during continuous venovenous hemodialysis with regional citrate anticoagulation. Am J Kidney Dis 33: e8
18. Ohtake Y, Hirasawa H, Sugai T, Oda S, Shiga H, Matsuda K 1991 Nafamostat mesilate as anticoagulant in continuous hemofiltration and continuous hemodiafiltration. Contrib Nephrol 93: 215-217
19. Paganini EP, O'Hara P, Nakamoto S 1984 Slow continuous ultrafiltration in hemodialysis-resistant oliguric acute renal failure patients. Trans Am Soc Artif Int Organs 30: 173-178
20. Palsson R, Niles JL 1999 Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding. Kidney Int 55: 1991-1997
21. Pinnick RV, Wiegmann TB, Diederich DA 1983 Regional citrate anticoagulation for hemodialysis in the patient at high risk for bleeding. N Engl J Med 308: 258-261
22. Ponikvar R, Kandus A, Buturovic C, Kveder R 1991 Use of prostacyclin as the only anticoagulant during continuous veno-venous hemofiltration. Contrib Nephrol 93: 218-220
23. Ronco C 1993 Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients. Clin Nephrol 40: 187-198
24. Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J 1997 Hemofiltration increases IL-6 clearance in early systemic inflammatory response syndrome but does not alter IL6 and TNF-alpha plasma concentrations. Intens Care Med 23: 878-884
25. Swartz RD 1981 Hemorrhage during high-risk hemodialysis using controlled heparinization. Nephron 28: 65-69
26. Swartz RD, Port FK 1979 Preventing hemorrhage in high-risk hemodialysis: regional versus low-dose heparin. Kidney Int 16: 513-518
27. Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG 2001 Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int 60: 370-374
28. Turney JH, Williams LC, Fewell MR, Parsons V, Weston MJ 1980 Platelet protection and heparin sparing with prostacyclin during regular dialysis therapy. Lancet 2: 219-222
29. van Geelen J, Vincent HH, Schalekamp MA 1988 Continuous arteriovenous haemofiltration and haemodiafiltration in acute renal failure. Nephrol Dial Transplant 3: 181-186
30. Zusman RM, Rubin RH, Cato AE, Cocchetto DM, Crow JW, Tolkoff-Rubin N 1981 Hemodialysis using prostacyclin instead of heparin as the sole antithrombotic agent. N Engl J Med 304: 934-939